GST/GSH Affinity Hydrogel for Localized Polypeptide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods often result in non-specific distribution, leading to reduced efficacy and increased toxicity due to the inability to target diseased tissues effectively, necessitating the development of localized and targeted delivery systems for therapeutic agents.
Innovation Solution
A hydrogel composition comprising poly(ethylene glycol) diacrylate (PEGDA) linked to glutathione (GSH) with therapeutic polypeptides covalently linked to glutathione s-transferase (GST), where the polypeptides are immobilized on the hydrogel surface and released via protease activation, specifically targeting vascular and proliferative diseases like diabetic retinopathy and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drug delivery methods are used, then drug distribution is achieved, but the distribution is non-specific leading to reduced efficacy and increased toxicity
Solution Approach 1:
The hydrogel composition is designed with localized therapeutic agent release at the disease site through protease-activated mechanisms. The hydrogel matrix provides localized delivery of polypeptide drugs, ensuring high concentration at the target site while minimizing systemic distribution and associated toxicity.
Solution Approach 2:
Proteases present at the disease site act as intermediaries to trigger controlled release of therapeutic polypeptides from the hydrogel. The protease-sensitive linkers in the hydrogel structure are cleaved by disease-specific proteases, enabling targeted activation of drug release only where the disease is present.
2Ease of operation
If non-specific drug delivery is used, then drug administration is simplified, but drug efficacy is reduced due to inability to target diseased tissues
Solution Approach 1:
The hydrogel system provides spatially differentiated drug release properties, with high release rates at the disease site (where proteases are present) and minimal release in healthy tissues. This localized quality ensures both ease of administration (single-site injection) and high therapeutic efficacy through targeted delivery.
Solution Approach 2:
The hydrogel's drug release parameters are dynamically changed by protease cleavage of sensitive linkers. In the presence of disease-specific proteases, the hydrogel transitions from a stable, retained state to a degraded, releasing state, enabling automatic adaptation of release parameters based on the local biochemical environment.
3Reliability
If targeted delivery system is developed, then treatment efficacy is enhanced, but system complexity increases
Solution Approach 1:
The hydrogel comprises a composite structure combining protease-sensitive linker molecules with therapeutic polypeptides and crosslinking agents. This composite material design integrates multiple functions (targeting, controlled release, structural integrity) into a single delivery system, enhancing efficacy while managing complexity through material-level integration rather than separate system components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system enables selective and localized release of therapeutic polypeptides, enhancing treatment efficacy while minimizing systemic toxicity by targeting specific disease sites, such as diabetic retinopathy and cancer, through controlled release mechanisms activated by proteases present at the disease site.
Implementation Method 1
a GST/GSH affinity hydrogel
Implementation Method 2
The one or more polypeptides may be linked to GST via a recognition site for a protease
Data Source
AI summary
Disclosed herein is a hydrogel composition comprising a polymer covalently linked to glutathione (GSH). Also disclosed herein is a method for providing localized delivery of one or more agents in a subject suffering from a disease. The method comprises administering to the subject a GST/GSH affinity hydrogel comprising a therapeutically effective amount of the one or more agents.